RMD

Business Profile & Competitive Position

ResMed Inc. (RMD) is classified in the Healthcare sector under the Medical - Devices industry. The company designs and markets cloud-connected medical devices used primarily to diagnose and treat sleep-disordered breathing, obstructive sleep apnea, and chronic respiratory conditions such as COPD. Its product mix includes continuous positive airway pressure (CPAP) and bilevel devices, ventilators, masks, and digital health software that tracks therapy adherence.

The financial profile supports the idea that ResMed sits in a relatively strong competitive position. Its net margin is 26.9% and its return on equity is 23.9%. Those figures are well above what is typical for many manufacturers and indicate that the company can price its products above cost while generating meaningful returns on shareholder capital. A beta of 0.75 also suggests RMD has historically moved less dramatically than the broader equity market, which is common for companies with steady, recurring demand from patients with chronic conditions.

That said, durable medical equipment is not a monopoly business. Competitors exist in masks and flow generators, and customer retention depends on both product efficacy and payer relationships. The margin and ROE numbers are positive signals, but they reflect past performance rather than a guarantee of future pricing power.

Financial Posture

ResMed currently trades with a market capitalization of $31.8 billion and a trailing P/E ratio of 21.0. That valuation sits at a level where investors appear to be paying for a profitable, lower-volatility healthcare franchise rather than treating the stock as a deep-value or hyper-growth name. The net margin of 26.9% and ROE of 23.9% give context to the multiple: a 21.0x P/E looks different when paired with margins near 27% and returns on equity approaching 24%.

The stock's last price was $219.475, with an RSI of 58.9 and the 50-day EMA at $206.86. That places the price slightly above its near-term moving average, though not at an extreme technical level. The beta of 0.75 reinforces the portrait of a defensive, healthcare-oriented equity, but valuation still matters because the P/E already embeds expectations of continued profitability.

Macro & Geopolitical Exposure

As a medical-device manufacturer, ResMed carries exposures that are typical for the Healthcare / Medical - Devices classification. The most direct macro risks include regulation and reimbursement policy. Devices sold in the United States face FDA oversight, while reimbursement levels are influenced by Medicare, Medicaid, and private insurers. Any changes to coverage criteria or reimbursement rates for sleep apnea therapy can flow directly through to revenue and margins.

Trade policy and supply-chain geography also matter. Medical devices rely on electronics, semiconductors, plastics, and precision components that are sourced globally. Tariffs, export restrictions, or logistical disruptions can raise input costs or limit availability. Additionally, because ResMed generates sales outside the U.S., currency fluctuations can affect reported results. Commodity-price movements in plastics and shipping costs, along with demographic trends such as aging populations, round out the macro variables that affect demand and cost structure in this corner of healthcare.

Recent Developments

ResMed's most recent quarterly reporting period produced a clear tension between reported results and forward guidance. On August 7, 2026, both Zacks and Reuters headlined that RMD shares fell despite a fourth-quarter earnings beat. Reuters specifically noted that a weak 2027 sales forecast eclipsed the quarterly profit beat. On the same day, GuruFocus reported that the Q4 2026 earnings call highlighted strong revenue growth and strategic portfolio shifts amid Astral headwinds. MarketBeat followed on August 9, 2026 with additional coverage of the Q4 earnings call highlights.

Together, these headlines tell a consistent story: ResMed delivered better-than-expected earnings and revenue growth, but the market's reaction was driven more by future growth concerns than by the rear-view results. The "Astral headwinds" reference points to specific product-line pressures that management addressed on the call.

Earnings Behavior & Post-Earnings Drift

ResMed has a strong track record of exceeding analyst estimates. Over the last 8 reported quarters, the company has beaten expectations 6 times, for a beat rate of 86%, with an average earnings surprise of 2.6%. Yet beating estimates has not reliably produced positive stock returns immediately after the reports.

The latest four quarters illustrate that disconnect. On August 6, 2026, ResMed reported actual EPS of $2.95 against an estimate of $2.89, a 2.1% positive surprise, and the stock fell 5.06% the next day. On April 30, 2026, actual EPS of $2.86 beat the $2.80 estimate by 2.1%, but the stock dropped 4.11% the next day and was down 3.24% over the following five sessions. The January 29, 2026 report showed a 2.6% surprise on actual EPS of $2.81 versus an estimate of $2.74, producing a modest 0.27% next-day gain and a 3.66% gain over five days. The October 30, 2025 quarter delivered a 1.6% beat on $2.55 actual versus $2.51 estimated, yet the stock fell 2.13% the next day and 1.03% over the next five sessions.

Averaging all post-earnings windows across the last eight quarters produces a 5-day post-earnings drift of -0.2%, classified as flat. In other words, simply buying after a beat has not generated meaningful directional profits historically. Looking ahead, ResMed's next scheduled earnings report is October 29, 2026 after the close, with a consensus EPS estimate of $2.83.

For a deeper dive into how institutional analysts are interpreting ResMed's valuation, forward guidance, and competitive standing, review the full institutional verdict on the ticker page. Cross-referencing the 86% beat rate, the flat post-earnings drift, and the weak 2027 sales outlook with upgraded or downgraded price assumptions can help frame what the market is currently pricing in.